



REDUCE

Subgroup analysis report

Asian Sites

12 February 2020

DIAGRAM B.V.



Table 1.1 History

| | European Sites | | | | Asian Sites | | | |
|-------------------------------|--------------------------|---------------------------|---------------------|------------|--------------------------|---------------------------|---------------------|------------|
| | 3 months DAPT (N=528) | 12 months DAPT (N=519) | Overall (N=1047) | P value | 3 months DAPT (N=223) | 12 months DAPT (N=226) | Overall (N=449) | P value |
| Age | | | | 0.9237 | | | | 0.0869 |
| | (n =528) | (n =519) | (n =1047) | . | (n =223) | (n =226) | (n =449) | . |
| Range | 35.00 - 93.00 | 33.00 - 91.00 | 33.00 - 93.00 | . | 22.00 - 85.00 | 25.00 - 88.00 | 22.00 - 88.00 | . |
| Median (Q1-Q3) | 63.00 (54.00-70.00) | 62.00 (54.00-70.00) | 62.00 (54.00-70.00) | . | 57.00 (48.00-65.00) | 54.50 (46.00-63.00) | 56.00 (47.00-64.00) | . |
| Mean ± SD | 62.87 ± 11.10 | 62.83 ± 11.49 | 62.85 ± 11.29 | . | 57.05 ± 11.88 | 55.25 ± 11.59 | 56.14 ± 11.76 | . |
| Sex (numerical) | | | | 0.0026 | | | | 0.8456 |
| Female | 101/528 (19.1%) | 140/519 (27.0%) | 241/1047 (23.0%) | . | 30/223 (13.5%) | 29/226 (12.8%) | 59/449 (13.1%) | . |
| Male | 427/528 (80.9%) | 379/519 (73.0%) | 806/1047 (77.0%) | . | 193/223 (86.5%) | 197/226 (87.2%) | 390/449 (86.9%) | . |
| Race (numerical) | | | | 0.0971 | | | | 0.9538 |
| Caucasian | 512/528 (97.0%) | 509/519 (98.1%) | 1021/1047 (97.5%) | . | 0/223 (0.0%) | 0/226 (0.0%) | 0/449 (0.0%) | . |
| Negroid | 0/528 (0.0%) | 3/519 (0.6%) | 3/1047 (0.3%) | . | 1/223 (0.4%) | 1/226 (0.4%) | 2/449 (0.4%) | . |
| Oriental | 7/528 (1.3%) | 3/519 (0.6%) | 10/1047 (1.0%) | . | 176/223 (78.9%) | 177/226 (78.3%) | 353/449 (78.6%) | . |
| Other | 9/528 (1.7%) | 4/519 (0.8%) | 13/1047 (1.2%) | . | 46/223 (20.6%) | 48/226 (21.2%) | 94/449 (20.9%) | . |
| Race | | | | 0.4922 | | | | 1.0000 |
| Caucasian | 517/527 (98.1%) | 509/519 (98.1%) | 1026/1046 (98.1%) | . | 0/223 (0.0%) | 0/226 (0.0%) | 0/449 (0.0%) | . |
| Negroid | 1/527 (0.2%) | 4/519 (0.8%) | 5/1046 (0.5%) | . | 1/223 (0.4%) | 1/226 (0.4%) | 2/449 (0.4%) | . |
| Oriental | 7/527 (1.3%) | 4/519 (0.8%) | 11/1046 (1.1%) | . | 222/223 (99.6%) | 225/226 (99.6%) | 447/449 (99.6%) | . |
| Other | 2/527 (0.4%) | 2/519 (0.4%) | 4/1046 (0.4%) | . | 0/223 (0.0%) | 0/226 (0.0%) | 0/449 (0.0%) | . |
| Asian sites | | | | . | | | | . |
| No | 528/528 (100.0%) | 519/519 (100.0%) | 1047/1047 (100.0%) | . | 0/223 (0.0%) | 0/226 (0.0%) | 0/449 (0.0%) | . |
| Yes | 0/528 (0.0%) | 0/519 (0.0%) | 0/1047 (0.0%) | . | 223/223 (100.0%) | 226/226 (100.0%) | 449/449 (100.0%) | . |
| Diagnosis for hospitalisation | | | | 0.1315 | | | | 0.0968 |
| STEMI | 232/528 (43.9%) | 197/518 (38.0%) | 429/1046 (41.0%) | . | 138/223 (61.9%) | 139/226 (61.5%) | 277/449 (61.7%) | . |
| non STEMI | 211/528 (40.0%) | 235/518 (45.4%) | 446/1046 (42.6%) | . | 56/223 (25.1%) | 70/226 (31.0%) | 126/449 (28.1%) | . |
| Unstable Angina | 85/528 (16.1%) | 86/518 (16.6%) | 171/1046 (16.3%) | . | 29/223 (13.0%) | 17/226 (7.5%) | 46/449 (10.2%) | . |
| Stemi | | | | 0.0521 | | | | 0.9342 |
| No | 296/528 (56.1%) | 321/518 (62.0%) | 617/1046 (59.0%) | . | 85/223 (38.1%) | 87/226 (38.5%) | 172/449 (38.3%) | . |

| | European Sites | | | | Asian Sites | | | |
|-----------------------------------|--------------------------|---------------------------|---------------------|------------|--------------------------|---------------------------|--------------------|------------|
| | 3 months DAPT (N=528) | 12 months DAPT (N=519) | Overall (N=1047) | P value | 3 months DAPT (N=223) | 12 months DAPT (N=226) | Overall (N=449) | P value |
| Yes | 232/528 (43.9%) | 197/518 (38.0%) | 429/1046 (41.0%) | . | 138/223 (61.9%) | 139/226 (61.5%) | 277/449 (61.7%) | . |
| Diabetes mellitus | | | | 0.4556 | | | | 0.4829 |
| No | 443/527 (84.1%) | 444/518 (85.7%) | 887/1045 (84.9%) | . | 146/223 (65.5%) | 155/226 (68.6%) | 301/449 (67.0%) | . |
| Yes | 84/527 (15.9%) | 74/518 (14.3%) | 158/1045 (15.1%) | . | 77/223 (34.5%) | 71/226 (31.4%) | 148/449 (33.0%) | . |
| Tobacco use | | | | 0.4630 | | | | 0.1404 |
| No | 305/521 (58.5%) | 310/510 (60.8%) | 615/1031 (59.7%) | . | 126/223 (56.5%) | 112/226 (49.6%) | 238/449 (53.0%) | . |
| Yes | 216/521 (41.5%) | 200/510 (39.2%) | 416/1031 (40.3%) | . | 97/223 (43.5%) | 114/226 (50.4%) | 211/449 (47.0%) | . |
| Hypercholesterolemia | | | | 0.4600 | | | | 0.0319 |
| No | 312/525 (59.4%) | 295/516 (57.2%) | 607/1041 (58.3%) | . | 90/223 (40.4%) | 114/226 (50.4%) | 204/449 (45.4%) | . |
| Yes | 213/525 (40.6%) | 221/516 (42.8%) | 434/1041 (41.7%) | . | 133/223 (59.6%) | 112/226 (49.6%) | 245/449 (54.6%) | . |
| Hypertension | | | | 0.5907 | | | | 0.4287 |
| No | 266/525 (50.7%) | 269/514 (52.3%) | 535/1039 (51.5%) | . | 103/223 (46.2%) | 96/226 (42.5%) | 199/449 (44.3%) | . |
| Yes | 259/525 (49.3%) | 245/514 (47.7%) | 504/1039 (48.5%) | . | 120/223 (53.8%) | 130/226 (57.5%) | 250/449 (55.7%) | . |
| Family history of CAD | | | | 0.3203 | | | | 0.3857 |
| No | 314/520 (60.4%) | 293/511 (57.3%) | 607/1031 (58.9%) | . | 169/223 (75.8%) | 179/226 (79.2%) | 348/449 (77.5%) | . |
| Yes | 206/520 (39.6%) | 218/511 (42.7%) | 424/1031 (41.1%) | . | 54/223 (24.2%) | 47/226 (20.8%) | 101/449 (22.5%) | . |
| Previous ACS (before current ACS) | | | | 0.6752 | | | | 0.9647 |
| No | 454/528 (86.0%) | 450/518 (86.9%) | 904/1046 (86.4%) | . | 203/223 (91.0%) | 206/226 (91.2%) | 409/449 (91.1%) | . |
| Yes | 74/528 (14.0%) | 68/518 (13.1%) | 142/1046 (13.6%) | . | 20/223 (9.0%) | 20/226 (8.8%) | 40/449 (8.9%) | . |
| Previous PCI | | | | 0.5151 | | | | 0.1422 |
| No | 460/528 (87.1%) | 459/519 (88.4%) | 919/1047 (87.8%) | . | 202/223 (90.6%) | 213/226 (94.2%) | 415/449 (92.4%) | . |
| Yes | 68/528 (12.9%) | 60/519 (11.6%) | 128/1047 (12.2%) | . | 21/223 (9.4%) | 13/226 (5.8%) | 34/449 (7.6%) | . |
| Previous CABG | | | | 0.5704 | | | | 0.2458 |
| No | 512/528 (97.0%) | 500/519 (96.3%) | 1012/1047 (96.7%) | . | 218/223 (97.8%) | 224/226 (99.1%) | 442/449 (98.4%) | . |
| Yes | 16/528 (3.0%) | 19/519 (3.7%) | 35/1047 (3.3%) | . | 5/223 (2.2%) | 2/226 (0.9%) | 7/449 (1.6%) | . |
| Previous CVA | | | | 0.9724 | | | | 0.2084 |
| No | 520/528 (98.5%) | 511/519 (98.5%) | 1031/1047 (98.5%) | . | 220/223 (98.7%) | 219/226 (96.9%) | 439/449 (97.8%) | . |

Table 1.1 History

| | European Sites | | | | Asian Sites | | | |
|---|-----------------------|------------------------|---------------------|---------|-----------------------|------------------------|---------------------|---------|
| | 3 months DAPT (N=528) | 12 months DAPT (N=519) | Overall (N=1047) | P value | 3 months DAPT (N=223) | 12 months DAPT (N=226) | Overall (N=449) | P value |
| Yes | 8/528 (1.5%) | 8/519 (1.5%) | 16/1047 (1.5%) | . | 3/223 (1.3%) | 7/226 (3.1%) | 10/449 (2.2%) | . |
| Known angina before current ACS | | | | 0.6269 | | | | 0.8430 |
| No | 461/528 (87.3%) | 447/518 (86.3%) | 908/1046 (86.8%) | . | 196/223 (87.9%) | 200/226 (88.5%) | 396/449 (88.2%) | . |
| Yes | 67/528 (12.7%) | 71/518 (13.7%) | 138/1046 (13.2%) | . | 27/223 (12.1%) | 26/226 (11.5%) | 53/449 (11.8%) | . |
| Killip class upon arrival at PCI centre | | | | 0.7604 | | | | 0.4349 |
| Class I | 494/525 (94.1%) | 478/515 (92.8%) | 972/1040 (93.5%) | . | 166/210 (79.0%) | 165/212 (77.8%) | 331/422 (78.4%) | . |
| Class II | 24/525 (4.6%) | 31/515 (6.0%) | 55/1040 (5.3%) | . | 39/210 (18.6%) | 36/212 (17.0%) | 75/422 (17.8%) | . |
| Class III | 5/525 (1.0%) | 4/515 (0.8%) | 9/1040 (0.9%) | . | 1/210 (0.5%) | 4/212 (1.9%) | 5/422 (1.2%) | . |
| Class IV | 2/525 (0.4%) | 2/515 (0.4%) | 4/1040 (0.4%) | . | 4/210 (1.9%) | 7/212 (3.3%) | 11/422 (2.6%) | . |
| Systolic blood pressure (mmHg) | | | | 0.2071 | | | | 0.9542 |
| | (n =526) | (n =514) | (n =1040) | . | (n =223) | (n =226) | (n =449) | . |
| Median (Q1-Q3) | 135.0 (120.0-150.0) | 137.0 (120.0-154.0) | 135.0 (120.0-152.0) | . | 130.0 (117.0-148.0) | 131.0 (117.0-146.0) | 131.0 (117.0-147.0) | . |
| Mean ± SD | 136.0 ± 26.38 | 137.9 ± 27.97 | 137.0 ± 27.18 | . | 132.9 ± 24.44 | 133.0 ± 23.82 | 133.0 ± 24.10 | . |
| Range | 80.00 - 260.00 | 70.00 - 240.00 | 70.00 - 260.00 | . | 84.00 - 249.00 | 81.00 - 230.00 | 81.00 - 249.00 | . |
| Diastolic blood pressure (mmHg) | | | | 0.9365 | | | | 0.7880 |
| | (n =526) | (n =514) | (n =1040) | . | (n =223) | (n =226) | (n =449) | . |
| Range | 40.00 - 140.00 | 20.00 - 142.00 | 20.00 - 142.00 | . | 48.00 - 117.00 | 44.00 - 130.00 | 44.00 - 130.00 | . |
| Median (Q1-Q3) | 78.00 (69.00-88.00) | 78.00 (67.00-90.00) | 78.00 (68.00-89.00) | . | 80.00 (70.00-89.00) | 80.00 (70.00-90.00) | 80.00 (70.00-90.00) | . |
| Mean ± SD | 78.23 ± 15.88 | 78.17 ± 16.12 | 78.20 ± 15.99 | . | 79.99 ± 13.66 | 79.95 ± 14.10 | 79.97 ± 13.87 | . |
| Heart rate (beats/min) | | | | 0.4943 | | | | 0.6682 |
| | (n =526) | (n =515) | (n =1041) | . | (n =223) | (n =226) | (n =449) | . |
| Range | 30.00 - 148.00 | 34.00 - 158.00 | 30.00 - 158.00 | . | 41.00 - 137.00 | 35.00 - 128.00 | 35.00 - 137.00 | . |
| Median (Q1-Q3) | 72.00 (63.00-81.00) | 71.00 (62.00-81.00) | 72.00 (63.00-81.00) | . | 79.00 (66.00-88.00) | 76.00 (66.00-88.00) | 77.00 (66.00-88.00) | . |
| Mean ± SD | 73.59 ± 14.88 | 72.88 ± 15.68 | 73.24 ± 15.27 | . | 77.99 ± 15.61 | 77.66 ± 15.37 | 77.82 ± 15.47 | . |
| Height (cm) | | | | 0.0032 | | | | 0.3416 |
| | (n =505) | (n =503) | (n =1008) | . | (n =218) | (n =224) | (n =442) | . |
| Range | 145.00 - 198.00 | 145.00 - 197.00 | 145.00 - 198.00 | . | 145.00 - 186.00 | 141.00 - 189.00 | 141.00 - 189.00 | . |

| | European Sites | | | | Asian Sites | | | |
|--|--------------------------|---------------------------|---------------------|------------|--------------------------|---------------------------|---------------------|------------|
| | 3 months DAPT (N=528) | 12 months DAPT (N=519) | Overall (N=1047) | P value | 3 months DAPT (N=223) | 12 months DAPT (N=226) | Overall (N=449) | P value |
| Mean ± SD | 174.7 ± 9.19 | 172.9 ± 9.42 | 173.8 ± 9.35 | . | 165.4 ± 7.77 | 164.8 ± 8.13 | 165.1 ± 7.95 | . |
| Median (Q1-Q3) | 175.0 (170.0-180.0) | 173.0 (165.0-180.0) | 174.0 (168.0-180.0) | . | 166.0 (160.0-170.0) | 165.0 (160.0-170.0) | 165.0 (160.0-170.0) | . |
| Weight (kg) | | | | 0.0095 | | | | 0.3935 |
| | (n =509) | (n =505) | (n =1014) | . | (n =219) | (n =224) | (n =443) | . |
| Range | 42.00 - 169.00 | 48.00 - 150.00 | 42.00 - 169.00 | . | 39.00 - 120.00 | 40.00 - 125.00 | 39.00 - 125.00 | . |
| Median (Q1-Q3) | 83.00 (74.00-93.00) | 80.00 (72.00-91.00) | 82.00 (73.00-92.00) | . | 70.00 (62.00-80.00) | 70.50 (64.00-78.00) | 70.00 (63.00-79.00) | . |
| Mean ± SD | 84.13 ± 15.93 | 81.52 ± 14.67 | 82.83 ± 15.37 | . | 71.07 ± 14.01 | 71.73 ± 13.19 | 71.40 ± 13.59 | . |
| Body Mass Index (kg/m ²) | | | | 0.3755 | | | | 0.1865 |
| | (n =505) | (n =503) | (n =1008) | . | (n =218) | (n =224) | (n =442) | . |
| Range | 17.97 - 44.05 | 19.05 - 48.98 | 17.97 - 48.98 | . | 15.92 - 45.12 | 17.58 - 46.88 | 15.92 - 46.88 | . |
| Median (Q1-Q3) | 26.88 (24.49-30.04) | 26.77 (24.49-29.67) | 26.83 (24.49-29.73) | . | 25.39 (22.72-28.40) | 26.07 (23.44-28.72) | 25.75 (23.12-28.69) | . |
| Mean ± SD | 27.47 ± 4.27 | 27.23 ± 4.10 | 27.35 ± 4.19 | . | 25.98 ± 4.95 | 26.37 ± 4.32 | 26.18 ± 4.64 | . |
| Baseline ECG available | | | | 0.3786 | | | | 0.7431 |
| No | 52/528 (9.8%) | 43/519 (8.3%) | 95/1047 (9.1%) | . | 6/223 (2.7%) | 5/226 (2.2%) | 11/449 (2.4%) | . |
| Yes | 476/528 (90.2%) | 476/519 (91.7%) | 952/1047 (90.9%) | . | 217/223 (97.3%) | 221/226 (97.8%) | 438/449 (97.6%) | . |
| Blood sample taken prior randomisation | | | | 0.9675 | | | | 0.6901 |
| No | 11/528 (2.1%) | 11/519 (2.1%) | 22/1047 (2.1%) | . | 4/223 (1.8%) | 3/226 (1.3%) | 7/449 (1.6%) | . |
| Yes | 517/528 (97.9%) | 508/519 (97.9%) | 1025/1047 (97.9%) | . | 219/223 (98.2%) | 223/226 (98.7%) | 442/449 (98.4%) | . |
| Creatinin (umol/l) | | | | 0.8132 | | | | 0.4024 |
| | (n =512) | (n =499) | (n =1011) | . | (n =213) | (n =220) | (n =433) | . |
| Range | 33.59 - 434.04 | 38.01 - 201.00 | 33.59 - 434.04 | . | 16.00 - 206.00 | 42.00 - 238.68 | 16.00 - 238.68 | . |
| Median (Q1-Q3) | 79.78 (69.00-92.00) | 80.00 (70.00-93.00) | 80.00 (69.84-92.00) | . | 84.00 (71.00-99.00) | 87.00 (73.50-99.00) | 85.00 (72.00-99.00) | . |
| Mean ± SD | 84.25 ± 27.55 | 83.49 ± 22.09 | 83.88 ± 25.00 | . | 88.32 ± 27.10 | 89.34 ± 25.50 | 88.84 ± 26.27 | . |
| BUN (mmol/l) | | | | 0.1150 | | | | 0.7240 |
| | (n =410) | (n =402) | (n =812) | . | (n =91) | (n =92) | (n =183) | . |
| Range | 1.11 - 17.14 | 0.14 - 36.00 | 0.14 - 36.00 | . | 0.84 - 10.00 | 1.09 - 11.10 | 0.84 - 11.10 | . |
| Median (Q1-Q3) | 5.16 (3.65- 6.90) | 5.00 (3.30- 6.68) | 5.10 (3.50- 6.80) | . | 4.10 (2.48- 5.50) | 3.90 (2.70- 5.50) | 3.93 (2.50- 5.50) | . |

| | European Sites | | | | Asian Sites | | | |
|----------------------------|--------------------------|---------------------------|---------------------|------------|--------------------------|---------------------------|--------------------|------------|
| | 3 months DAPT (N=528) | 12 months DAPT (N=519) | Overall (N=1047) | P value | 3 months DAPT (N=223) | 12 months DAPT (N=226) | Overall (N=449) | P value |
| Mean ± SD | 5.53 ± 2.58 | 5.27 ± 2.84 | 5.40 ± 2.71 | . | 4.16 ± 2.01 | 4.31 ± 2.06 | 4.23 ± 2.03 | . |
| Glucose (mmol/l) | | | | 0.6277 | | | | 0.5599 |
| | (n =463) | (n =459) | (n =922) | . | (n =169) | (n =178) | (n =347) | . |
| Range | 2.78 - 36.80 | 2.70 - 28.20 | 2.70 - 36.80 | . | 0.38 - 30.80 | 4.05 - 23.31 | 0.38 - 30.80 | . |
| Median (Q1-Q3) | 6.70 (5.77- 8.40) | 6.60 (5.72- 8.21) | 6.63 (5.72- 8.38) | . | 6.88 (5.90- 9.40) | 6.95 (6.10- 9.46) | 6.90 (6.00- 9.46) | . |
| Mean ± SD | 7.60 ± 3.39 | 7.48 ± 2.91 | 7.54 ± 3.16 | . | 8.32 ± 4.21 | 8.34 ± 3.70 | 8.33 ± 3.95 | . |
| Hemoglobin (mmol/l) | | | | 0.6427 | | | | 0.4175 |
| | (n =455) | (n =445) | (n =900) | . | (n =200) | (n =196) | (n =396) | . |
| Range | 5.77 - 11.50 | 6.20 - 12.30 | 5.77 - 12.30 | . | 5.71 - 13.65 | 5.14 - 16.90 | 5.14 - 16.90 | . |
| Mean ± SD | 8.98 ± 0.92 | 8.98 ± 0.97 | 8.98 ± 0.94 | . | 8.96 ± 1.15 | 9.11 ± 1.23 | 9.03 ± 1.19 | . |
| Median (Q1-Q3) | 9.10 (8.40- 9.60) | 9.00 (8.38- 9.62) | 9.06 (8.40- 9.60) | . | 9.00 (8.38- 9.62) | 9.12 (8.44- 9.77) | 9.06 (8.38- 9.74) | . |
| Total cholesterol (mmol/l) | | | | 0.1435 | | | | 0.6704 |
| | (n =385) | (n =387) | (n =772) | . | (n =152) | (n =166) | (n =318) | . |
| Range | 2.10 - 8.70 | 2.20 - 9.40 | 2.10 - 9.40 | . | 2.20 - 11.37 | 2.40 - 10.80 | 2.20 - 11.37 | . |
| Median (Q1-Q3) | 4.97 (4.20- 5.70) | 5.08 (4.30- 5.80) | 5.00 (4.26- 5.76) | . | 5.20 (4.43- 5.90) | 5.11 (4.40- 5.83) | 5.19 (4.40- 5.90) | . |
| Mean ± SD | 4.96 ± 1.13 | 5.12 ± 1.21 | 5.04 ± 1.17 | . | 5.25 ± 1.36 | 5.19 ± 1.31 | 5.22 ± 1.33 | . |
| HDL (mmol/l) | | | | 0.1799 | | | | 0.1794 |
| | (n =330) | (n =328) | (n =658) | . | (n =151) | (n =164) | (n =315) | . |
| Range | 0.39 - 3.24 | 0.48 - 2.80 | 0.39 - 3.24 | . | 0.50 - 2.07 | 0.50 - 2.05 | 0.50 - 2.07 | . |
| Median (Q1-Q3) | 1.05 (0.88- 1.27) | 1.10 (0.90- 1.30) | 1.07 (0.88- 1.29) | . | 1.01 (0.88- 1.20) | 0.99 (0.84- 1.15) | 1.00 (0.85- 1.20) | . |
| Mean ± SD | 1.12 ± 0.37 | 1.14 ± 0.35 | 1.13 ± 0.36 | . | 1.05 ± 0.25 | 1.02 ± 0.25 | 1.03 ± 0.25 | . |
| LDL (mmol/l) | | | | 0.8044 | | | | 0.4328 |
| | (n =319) | (n =315) | (n =634) | . | (n =151) | (n =163) | (n =314) | . |
| Range | 0.70 - 6.58 | 0.65 - 6.15 | 0.65 - 6.58 | . | 0.90 - 9.97 | 0.80 - 9.20 | 0.80 - 9.97 | . |
| Median (Q1-Q3) | 3.00 (2.25- 3.70) | 3.06 (2.31- 3.80) | 3.03 (2.30- 3.73) | . | 3.52 (2.64- 4.17) | 3.30 (2.60- 4.18) | 3.45 (2.62- 4.17) | . |
| Mean ± SD | 3.04 ± 1.03 | 3.06 ± 1.01 | 3.05 ± 1.02 | . | 3.53 ± 1.29 | 3.44 ± 1.26 | 3.48 ± 1.28 | . |
| Triglycerides (mmol/l) | | | | 0.1518 | | | | 0.5293 |

| | European Sites | | | | Asian Sites | | | |
|---------------------|--------------------------|---------------------------|---------------------|------------|--------------------------|---------------------------|---------------------|------------|
| | 3 months DAPT (N=528) | 12 months DAPT (N=519) | Overall (N=1047) | P value | 3 months DAPT (N=223) | 12 months DAPT (N=226) | Overall (N=449) | P value |
| | (n =327) | (n =328) | (n =655) | . | (n =152) | (n =167) | (n =319) | . |
| Range | 0.33 - 16.55 | 0.42 - 11.90 | 0.33 - 16.55 | . | 0.46 - 11.10 | 0.55 - 8.38 | 0.46 - 11.10 | . |
| Median (Q1-Q3) | 1.47 (1.06- 2.22) | 1.61 (1.05- 2.39) | 1.50 (1.05- 2.30) | . | 1.57 (1.17- 1.97) | 1.58 (1.13- 2.08) | 1.57 (1.16- 2.07) | . |
| Mean ± SD | 1.81 ± 1.41 | 1.99 ± 1.47 | 1.90 ± 1.44 | . | 1.73 ± 1.12 | 1.83 ± 1.12 | 1.78 ± 1.12 | . |
| CK (U/l (xxxxx)) | | | | 0.3565 | | | | 0.7524 |
| | (n =456) | (n =449) | (n =905) | . | (n =156) | (n =169) | (n =325) | . |
| Range | 36.00 - 10619 | 22.00 - 10000 | 22.00 - 10619 | . | 45.00 - 9924.0 | 45.00 - 7824.0 | 45.00 - 9924.0 | . |
| Median (Q1-Q3) | 263.0 (123.0-819.0) | 233.0 (110.0-802.0) | 244.0 (114.0-805.0) | . | 511.5 (143.0- 1875) | 476.0 (155.0- 1728) | 511.0 (153.0- 1768) | . |
| Mean ± SD | 735.9 ± 1195 | 692.6 ± 1118 | 714.4 ± 1157 | . | 1242 ± 1678 | 1291 ± 1600 | 1268 ± 1635 | . |
| CKmb (Ug/l (x,xx)) | | | | 0.6892 | | | | 0.3342 |
| | (n =235) | (n =233) | (n =468) | . | (n =109) | (n =120) | (n =229) | . |
| Range | 0.56 - 617.00 | 0.25 - 1980.0 | 0.25 - 1980.0 | . | 0.20 - 1960.0 | 0.00 - 1860.0 | 0.00 - 1960.0 | . |
| Median (Q1-Q3) | 27.60 (10.00-86.00) | 23.56 (11.00-85.00) | 25.74 (10.26-85.95) | . | 51.00 (17.80-129.0) | 35.50 (12.65-119.5) | 42.00 (13.00-125.0) | . |
| Mean ± SD | 72.28 ± 103.7 | 81.65 ± 195.4 | 76.95 ± 156.1 | . | 115.5 ± 223.3 | 109.6 ± 217.0 | 112.4 ± 219.5 | . |
| Troponin T (µg/L) | | | | 0.1403 | | | | 0.0082 |
| | (n =78) | (n =80) | (n =158) | . | (n =38) | (n =38) | (n =76) | . |
| Range | 0.01 - 101.00 | 0.01 - 12.10 | 0.01 - 101.00 | . | 0.03 - 10.00 | 0.01 - 7.78 | 0.01 - 10.00 | . |
| Median (Q1-Q3) | 0.21 (0.04- 1.07) | 0.41 (0.10- 1.23) | 0.34 (0.06- 1.19) | . | 3.39 (0.89- 6.73) | 1.04 (0.23- 3.79) | 2.00 (0.51- 5.38) | . |
| Mean ± SD | 2.52 ± 11.57 | 1.51 ± 2.61 | 2.01 ± 8.33 | . | 3.98 ± 3.27 | 2.15 ± 2.32 | 3.06 ± 2.96 | . |
| Troponin I (µg/L) | | | | 0.7065 | | | | 0.8396 |
| | (n =233) | (n =234) | (n =467) | . | (n =73) | (n =85) | (n =158) | . |
| Range | 0.01 - 400.00 | 0.01 - 10939 | 0.01 - 10939 | . | 0.00 - 90.00 | 0.00 - 90.00 | 0.00 - 90.00 | . |
| Mean ± SD | 33.27 ± 59.98 | 121.5 ± 763.4 | 77.48 ± 543.2 | . | 20.19 ± 29.26 | 17.84 ± 25.18 | 18.92 ± 27.08 | . |
| Median (Q1-Q3) | 7.10 (0.75-40.00) | 7.94 (0.56-40.00) | 7.70 (0.66-40.00) | . | 2.78 (0.36-30.00) | 4.57 (0.34-29.07) | 3.96 (0.34-30.00) | . |
| Troponin hsT (ng/L) | | | | 0.1122 | | | | 0.3827 |
| | (n =166) | (n =166) | (n =332) | . | (n =3) | (n =3) | (n =6) | . |
| Mean ± SD | 1456 ± 2363 | 1270 ± 2647 | 1363 ± 2507 | . | 7410 ± 11789 | 3807 ± 6358 | 5608 ± 8698 | . |

| | European Sites | | | | Asian Sites | | | |
|--------------------|--------------------------|---------------------------|---------------------|------------|--------------------------|---------------------------|---------------------|------------|
| | 3 months DAPT (N=528) | 12 months DAPT (N=519) | Overall (N=1047) | P value | 3 months DAPT (N=223) | 12 months DAPT (N=226) | Overall (N=449) | P value |
| Range | 4.00 - 15600 | 2.00 - 20847 | 2.00 - 20847 | . | 476.00 - 21022 | 34.80 - 11148 | 34.80 - 21022 | . |
| Median (Q1-Q3) | 434.0 (60.00- 1662) | 220.5 (50.00-984.0) | 311.5 (58.00- 1398) | . | 731.0 (476.0-21022) | 238.0 (34.80-11148) | 603.5 (238.0-11148) | . |
| Troponin T (ng/ml) | | | | 0.6695 | | | | 0.1903 |
| | (n =29) | (n =16) | (n =45) | . | (n =37) | (n =39) | (n =76) | . |
| Range | 0.04 - 5782.0 | 0.02 - 2942.0 | 0.02 - 5782.0 | . | 0.02 - 303.00 | 0.00 - 50.00 | 0.00 - 303.00 | . |
| Mean ± SD | 594.8 ± 1221 | 312.4 ± 725.5 | 494.4 ± 1071 | . | 10.51 ± 50.10 | 4.26 ± 10.01 | 7.30 ± 35.57 | . |
| Median (Q1-Q3) | 130.0 (7.00-501.0) | 61.20 (11.00-212.0) | 99.00 (9.00-292.0) | . | 0.52 (0.19- 1.30) | 1.00 (0.28- 3.44) | 0.66 (0.21- 2.00) | . |

| | European Sites | | | | Asian Sites | | | |
|---|-----------------------|------------------------|------------------|---------|-----------------------|------------------------|-----------------|---------|
| | 3 months DAPT (N=528) | 12 months DAPT (N=519) | Overall (N=1047) | P value | 3 months DAPT (N=223) | 12 months DAPT (N=226) | Overall (N=449) | P value |
| Vessel disease | | | | 0.1930 | | | | 0.9586 |
| One | 335/528 (63.4%) | 346/519 (66.7%) | 681/1047 (65.0%) | . | 145/223 (65.0%) | 146/226 (64.6%) | 291/449 (64.8%) | . |
| Two | 151/528 (28.6%) | 124/519 (23.9%) | 275/1047 (26.3%) | . | 58/223 (26.0%) | 61/226 (27.0%) | 119/449 (26.5%) | . |
| Three | 42/528 (8.0%) | 49/519 (9.4%) | 91/1047 (8.7%) | . | 20/223 (9.0%) | 19/226 (8.4%) | 39/449 (8.7%) | . |
| IRV | | | | 0.9940 | | | | 0.0078 |
| RCA | 182/528 (34.5%) | 181/519 (34.9%) | 363/1047 (34.7%) | . | 53/223 (23.8%) | 65/226 (28.8%) | 118/449 (26.3%) | . |
| LAD | 209/528 (39.6%) | 201/519 (38.7%) | 410/1047 (39.2%) | . | 151/223 (67.7%) | 128/226 (56.6%) | 279/449 (62.1%) | . |
| CX | 131/528 (24.8%) | 131/519 (25.2%) | 262/1047 (25.0%) | . | 15/223 (6.7%) | 33/226 (14.6%) | 48/449 (10.7%) | . |
| Left main | 0/528 (0.0%) | 0/519 (0.0%) | 0/1047 (0.0%) | . | 2/223 (0.9%) | 0/226 (0.0%) | 2/449 (0.4%) | . |
| Graft | 6/528 (1.1%) | 6/519 (1.2%) | 12/1047 (1.1%) | . | 2/223 (0.9%) | 0/226 (0.0%) | 2/449 (0.4%) | . |
| Infarct/Ischemia Related Segment number | | | | 0.4494 | | | | 0.1335 |
| 1 RCA proximal | 62/528 (11.7%) | 68/519 (13.1%) | 130/1047 (12.4%) | . | 25/223 (11.2%) | 28/226 (12.4%) | 53/449 (11.8%) | . |
| 2 RCA middle | 80/528 (15.2%) | 73/519 (14.1%) | 153/1047 (14.6%) | . | 15/223 (6.7%) | 26/226 (11.5%) | 41/449 (9.1%) | . |
| 3 RCA distal | 32/528 (6.1%) | 31/519 (6.0%) | 63/1047 (6.0%) | . | 12/223 (5.4%) | 11/226 (4.9%) | 23/449 (5.1%) | . |
| 4 RCA-RDP | 4/528 (0.8%) | 6/519 (1.2%) | 10/1047 (1.0%) | . | 0/223 (0.0%) | 0/226 (0.0%) | 0/449 (0.0%) | . |
| 5 Left main | 0/528 (0.0%) | 0/519 (0.0%) | 0/1047 (0.0%) | . | 2/223 (0.9%) | 0/226 (0.0%) | 2/449 (0.4%) | . |
| 6 LAD proximal | 89/528 (16.9%) | 98/519 (18.9%) | 187/1047 (17.9%) | . | 105/223 (47.1%) | 90/226 (39.8%) | 195/449 (43.4%) | . |
| 7 LAD middle | 104/528 (19.7%) | 85/519 (16.4%) | 189/1047 (18.1%) | . | 41/223 (18.4%) | 36/226 (15.9%) | 77/449 (17.1%) | . |
| 8 LAD distal | 3/528 (0.6%) | 5/519 (1.0%) | 8/1047 (0.8%) | . | 4/223 (1.8%) | 1/226 (0.4%) | 5/449 (1.1%) | . |
| 9 LAD-D1 | 12/528 (2.3%) | 10/519 (1.9%) | 22/1047 (2.1%) | . | 1/223 (0.4%) | 1/226 (0.4%) | 2/449 (0.4%) | . |
| 10 LAD-D2 | 1/528 (0.2%) | 3/519 (0.6%) | 4/1047 (0.4%) | . | 0/223 (0.0%) | 0/226 (0.0%) | 0/449 (0.0%) | . |
| 11 CX proximal | 38/528 (7.2%) | 41/519 (7.9%) | 79/1047 (7.5%) | . | 6/223 (2.7%) | 11/226 (4.9%) | 17/449 (3.8%) | . |
| 12 CX-MO | 57/528 (10.8%) | 39/519 (7.5%) | 96/1047 (9.2%) | . | 6/223 (2.7%) | 10/226 (4.4%) | 16/449 (3.6%) | . |
| 13 CX-distal | 30/528 (5.7%) | 36/519 (6.9%) | 66/1047 (6.3%) | . | 3/223 (1.3%) | 9/226 (4.0%) | 12/449 (2.7%) | . |
| 14 CX-PL | 4/528 (0.8%) | 14/519 (2.7%) | 18/1047 (1.7%) | . | 0/223 (0.0%) | 2/226 (0.9%) | 2/449 (0.4%) | . |
| 15 CX-LDP | 2/528 (0.4%) | 1/519 (0.2%) | 3/1047 (0.3%) | . | 0/223 (0.0%) | 1/226 (0.4%) | 1/449 (0.2%) | . |
| 16 RCA-RPL | 4/528 (0.8%) | 3/519 (0.6%) | 7/1047 (0.7%) | . | 1/223 (0.4%) | 0/226 (0.0%) | 1/449 (0.2%) | . |

| | European Sites | | | | Asian Sites | | | |
|------------------------------------|-----------------------|------------------------|-------------------|---------|-----------------------|------------------------|-----------------|---------|
| | 3 months DAPT (N=528) | 12 months DAPT (N=519) | Overall (N=1047) | P value | 3 months DAPT (N=223) | 12 months DAPT (N=226) | Overall (N=449) | P value |
| 17 Venous Graft | 6/528 (1.1%) | 6/519 (1.2%) | 12/1047 (1.1%) | . | 2/223 (0.9%) | 0/226 (0.0%) | 2/449 (0.4%) | . |
| 18 Arterial Graft | 0/528 (0.0%) | 0/519 (0.0%) | 0/1047 (0.0%) | . | 0/223 (0.0%) | 0/226 (0.0%) | 0/449 (0.0%) | . |
| Initial TIMI flow (culprit vessel) | | | | 0.7365 | | | | 0.9013 |
| 0 | 135/519 (26.0%) | 118/502 (23.5%) | 253/1021 (24.8%) | . | 64/222 (28.8%) | 59/226 (26.1%) | 123/448 (27.5%) | . |
| 1 | 37/519 (7.1%) | 34/502 (6.8%) | 71/1021 (7.0%) | . | 44/222 (19.8%) | 44/226 (19.5%) | 88/448 (19.6%) | . |
| 2 | 78/519 (15.0%) | 73/502 (14.5%) | 151/1021 (14.8%) | . | 38/222 (17.1%) | 43/226 (19.0%) | 81/448 (18.1%) | . |
| 3 | 269/519 (51.8%) | 277/502 (55.2%) | 546/1021 (53.5%) | . | 76/222 (34.2%) | 80/226 (35.4%) | 156/448 (34.8%) | . |
| Initial Timi Flow 3 | | | | 0.2835 | | | | 0.7960 |
| No | 250/519 (48.2%) | 225/502 (44.8%) | 475/1021 (46.5%) | . | 146/222 (65.8%) | 146/226 (64.6%) | 292/448 (65.2%) | . |
| Yes | 269/519 (51.8%) | 277/502 (55.2%) | 546/1021 (53.5%) | . | 76/222 (34.2%) | 80/226 (35.4%) | 156/448 (34.8%) | . |
| Access site | | | | 0.3037 | | | | 0.1192 |
| Femorals | 102/519 (19.7%) | 111/510 (21.8%) | 213/1029 (20.7%) | . | 73/223 (32.7%) | 58/226 (25.7%) | 131/449 (29.2%) | . |
| Radialis | 415/519 (80.0%) | 399/510 (78.2%) | 814/1029 (79.1%) | . | 150/223 (67.3%) | 167/226 (73.9%) | 317/449 (70.6%) | . |
| Brachialis | 2/519 (0.4%) | 0/510 (0.0%) | 2/1029 (0.2%) | . | 0/223 (0.0%) | 1/226 (0.4%) | 1/449 (0.2%) | . |
| Access site radialis | | | | 0.4959 | | | | 0.1232 |
| No | 104/519 (20.0%) | 111/510 (21.8%) | 215/1029 (20.9%) | . | 73/223 (32.7%) | 59/226 (26.1%) | 132/449 (29.4%) | . |
| Yes | 415/519 (80.0%) | 399/510 (78.2%) | 814/1029 (79.1%) | . | 150/223 (67.3%) | 167/226 (73.9%) | 317/449 (70.6%) | . |
| Balloon pre-dilatation | | | | 0.4171 | | | | 0.7651 |
| No | 163/526 (31.0%) | 173/519 (33.3%) | 336/1045 (32.2%) | . | 61/223 (27.4%) | 59/226 (26.1%) | 120/449 (26.7%) | . |
| Yes | 363/526 (69.0%) | 346/519 (66.7%) | 709/1045 (67.8%) | . | 162/223 (72.6%) | 167/226 (73.9%) | 329/449 (73.3%) | . |
| TIMI post (culprit lesion) | | | | 1.0000 | | | | 0.2461 |
| 0 | 0/526 (0.0%) | 0/517 (0.0%) | 0/1043 (0.0%) | . | 0/223 (0.0%) | 0/226 (0.0%) | 0/449 (0.0%) | . |
| 1 | 0/526 (0.0%) | 0/517 (0.0%) | 0/1043 (0.0%) | . | 0/223 (0.0%) | 0/226 (0.0%) | 0/449 (0.0%) | . |
| 2 | 1/526 (0.2%) | 0/517 (0.0%) | 1/1043 (0.1%) | . | 2/223 (0.9%) | 0/226 (0.0%) | 2/449 (0.4%) | . |
| 3 | 525/526 (99.8%) | 517/517 (100.0%) | 1042/1043 (99.9%) | . | 221/223 (99.1%) | 226/226 (100.0%) | 447/449 (99.6%) | . |
| Visual Ds post (culprit lesion) | | | | 0.4957 | | | | 0.4967 |
| < 20% | 528/528 (100.0%) | 518/519 (99.8%) | 1046/1047 (99.9%) | . | 222/223 (99.6%) | 226/226 (100.0%) | 448/449 (99.8%) | . |

| | European Sites | | | | Asian Sites | | | |
|--------------------------------|--------------------------|---------------------------|---------------------|------------|--------------------------|---------------------------|---------------------|------------|
| | 3 months DAPT (N=528) | 12 months DAPT (N=519) | Overall (N=1047) | P value | 3 months DAPT (N=223) | 12 months DAPT (N=226) | Overall (N=449) | P value |
| 20-50% | 0/528 (0.0%) | 1/519 (0.2%) | 1/1047 (0.1%) | . | 1/223 (0.4%) | 0/226 (0.0%) | 1/449 (0.2%) | . |
| >=50 % | 0/528 (0.0%) | 0/519 (0.0%) | 0/1047 (0.0%) | . | 0/223 (0.0%) | 0/226 (0.0%) | 0/449 (0.0%) | . |
| 100% | 0/528 (0.0%) | 0/519 (0.0%) | 0/1047 (0.0%) | . | 0/223 (0.0%) | 0/226 (0.0%) | 0/449 (0.0%) | . |
| Number of stents used | | | | 0.5837 | | | | 0.6553 |
| 1 | 440/528 (83.3%) | 431/519 (83.0%) | 871/1047 (83.2%) | . | 180/223 (80.7%) | 179/226 (79.2%) | 359/449 (80.0%) | . |
| 2 | 76/528 (14.4%) | 69/519 (13.3%) | 145/1047 (13.8%) | . | 37/223 (16.6%) | 43/226 (19.0%) | 80/449 (17.8%) | . |
| 3 | 11/528 (2.1%) | 17/519 (3.3%) | 28/1047 (2.7%) | . | 4/223 (1.8%) | 4/226 (1.8%) | 8/449 (1.8%) | . |
| 4 | 1/528 (0.2%) | 2/519 (0.4%) | 3/1047 (0.3%) | . | 2/223 (0.9%) | 0/226 (0.0%) | 2/449 (0.4%) | . |
| Total stent length (mm (x.xx)) | | | | 0.3635 | | | | 0.6495 |
| | (n =526) | (n =518) | (n =1044) | . | (n =223) | (n =226) | (n =449) | . |
| Median (Q1-Q3) | 23.00 (15.00-28.00) | 18.00 (18.00-28.00) | 23.00 (18.00-28.00) | . | 23.00 (18.00-33.00) | 23.00 (18.00-33.00) | 23.00 (18.00-33.00) | . |
| Mean ± SD | 24.02 ± 11.11 | 23.98 ± 12.22 | 24.00 ± 11.67 | . | 29.03 ± 15.66 | 27.93 ± 13.25 | 28.47 ± 14.49 | . |
| Range | 9.00 - 89.00 | 9.00 - 89.00 | 9.00 - 89.00 | . | 9.00 - 117.00 | 9.00 - 89.00 | 9.00 - 117.00 | . |
| Post dilatation | | | | 0.9552 | | | | 0.8799 |
| No | 270/527 (51.2%) | 265/519 (51.1%) | 535/1046 (51.1%) | . | 49/223 (22.0%) | 51/226 (22.6%) | 100/449 (22.3%) | . |
| Yes | 257/527 (48.8%) | 254/519 (48.9%) | 511/1046 (48.9%) | . | 174/223 (78.0%) | 175/226 (77.4%) | 349/449 (77.7%) | . |
| PCI succesful (culprit lesion) | | | | 1.0000 | | | | 0.2461 |
| No | 3/528 (0.6%) | 2/519 (0.4%) | 5/1047 (0.5%) | . | 2/223 (0.9%) | 0/226 (0.0%) | 2/449 (0.4%) | . |
| Yes | 525/528 (99.4%) | 517/519 (99.6%) | 1042/1047 (99.5%) | . | 221/223 (99.1%) | 226/226 (100.0%) | 447/449 (99.6%) | . |
| Additional devices used | | | | 0.2786 | | | | 0.3879 |
| No | 460/527 (87.3%) | 441/519 (85.0%) | 901/1046 (86.1%) | . | 181/223 (81.2%) | 176/226 (77.9%) | 357/449 (79.5%) | . |
| Yes | 67/527 (12.7%) | 78/519 (15.0%) | 145/1046 (13.9%) | . | 42/223 (18.8%) | 50/226 (22.1%) | 92/449 (20.5%) | . |
| Embolic protection | | | | . | | | | 0.1982 |
| No | 528/528 (100.0%) | 519/519 (100.0%) | 1047/1047 (100.0%) | . | 218/223 (97.8%) | 216/226 (95.6%) | 434/449 (96.7%) | . |
| Yes | 0/528 (0.0%) | 0/519 (0.0%) | 0/1047 (0.0%) | . | 5/223 (2.2%) | 10/226 (4.4%) | 15/449 (3.3%) | . |
| Thrombosuction | | | | 0.5011 | | | | 0.9438 |
| No | 468/528 (88.6%) | 453/519 (87.3%) | 921/1047 (88.0%) | . | 189/223 (84.8%) | 191/226 (84.5%) | 380/449 (84.6%) | . |

| | European Sites | | | | Asian Sites | | | |
|--|--------------------------|---------------------------|---------------------|------------|--------------------------|---------------------------|--------------------|------------|
| | 3 months DAPT (N=528) | 12 months DAPT (N=519) | Overall (N=1047) | P value | 3 months DAPT (N=223) | 12 months DAPT (N=226) | Overall (N=449) | P value |
| Yes | 60/528 (11.4%) | 66/519 (12.7%) | 126/1047 (12.0%) | . | 34/223 (15.2%) | 35/226 (15.5%) | 69/449 (15.4%) | . |
| Distal protection | | | | 1.0000 | | | | . |
| No | 527/528 (99.8%) | 519/519 (100.0%) | 1046/1047 (99.9%) | . | 223/223 (100.0%) | 226/226 (100.0%) | 449/449 (100.0%) | . |
| Yes | 1/528 (0.2%) | 0/519 (0.0%) | 1/1047 (0.1%) | . | 0/223 (0.0%) | 0/226 (0.0%) | 0/449 (0.0%) | . |
| IABP | | | | . | | | | 1.0000 |
| No | 528/528 (100.0%) | 519/519 (100.0%) | 1047/1047 (100.0%) | . | 222/223 (99.6%) | 225/226 (99.6%) | 447/449 (99.6%) | . |
| Yes | 0/528 (0.0%) | 0/519 (0.0%) | 0/1047 (0.0%) | . | 1/223 (0.4%) | 1/226 (0.4%) | 2/449 (0.4%) | . |
| Other additional devices used | | | | 0.1823 | | | | 0.9848 |
| No | 520/528 (98.5%) | 505/519 (97.3%) | 1025/1047 (97.9%) | . | 219/223 (98.2%) | 222/226 (98.2%) | 441/449 (98.2%) | . |
| Yes | 8/528 (1.5%) | 14/519 (2.7%) | 22/1047 (2.1%) | . | 4/223 (1.8%) | 4/226 (1.8%) | 8/449 (1.8%) | . |
| Additional segments dilated during hospitalisation | | | | 0.5458 | | | | 0.6382 |
| No | 428/528 (81.1%) | 413/519 (79.6%) | 841/1047 (80.3%) | . | 171/223 (76.7%) | 169/226 (74.8%) | 340/449 (75.7%) | . |
| Yes | 100/528 (18.9%) | 106/519 (20.4%) | 206/1047 (19.7%) | . | 52/223 (23.3%) | 57/226 (25.2%) | 109/449 (24.3%) | . |
| Other (non culprit) significant lesion | | | | 0.8784 | | | | 0.8290 |
| No | 367/528 (69.5%) | 363/519 (69.9%) | 730/1047 (69.7%) | . | 157/223 (70.4%) | 157/226 (69.5%) | 314/449 (69.9%) | . |
| Yes | 161/528 (30.5%) | 156/519 (30.1%) | 317/1047 (30.3%) | . | 66/223 (29.6%) | 69/226 (30.5%) | 135/449 (30.1%) | . |
| LAD | | | | 0.6985 | | | | 0.9557 |
| No | 466/528 (88.3%) | 454/519 (87.5%) | 920/1047 (87.9%) | . | 193/223 (86.5%) | 196/226 (86.7%) | 389/449 (86.6%) | . |
| Yes | 62/528 (11.7%) | 65/519 (12.5%) | 127/1047 (12.1%) | . | 30/223 (13.5%) | 30/226 (13.3%) | 60/449 (13.4%) | . |
| RCA | | | | 0.4678 | | | | 0.9189 |
| No | 482/528 (91.3%) | 467/519 (90.0%) | 949/1047 (90.6%) | . | 199/223 (89.2%) | 201/226 (88.9%) | 400/449 (89.1%) | . |
| Yes | 46/528 (8.7%) | 52/519 (10.0%) | 98/1047 (9.4%) | . | 24/223 (10.8%) | 25/226 (11.1%) | 49/449 (10.9%) | . |
| CX | | | | 0.3563 | | | | 0.8448 |
| No | 457/528 (86.6%) | 459/519 (88.4%) | 916/1047 (87.5%) | . | 194/223 (87.0%) | 198/226 (87.6%) | 392/449 (87.3%) | . |
| Yes | 71/528 (13.4%) | 60/519 (11.6%) | 131/1047 (12.5%) | . | 29/223 (13.0%) | 28/226 (12.4%) | 57/449 (12.7%) | . |
| Multivessel disease | | | | 0.2747 | | | | 0.9256 |
| No | 335/528 (63.4%) | 346/519 (66.7%) | 681/1047 (65.0%) | . | 145/223 (65.0%) | 146/226 (64.6%) | 291/449 (64.8%) | . |

| | European Sites | | | | Asian Sites | | | |
|-------------|--------------------------|---------------------------|---------------------|------------|--------------------------|---------------------------|--------------------|------------|
| | 3 months DAPT (N=528) | 12 months DAPT (N=519) | Overall (N=1047) | P value | 3 months DAPT (N=223) | 12 months DAPT (N=226) | Overall (N=449) | P value |
| Yes | 193/528 (36.6%) | 173/519 (33.3%) | 366/1047 (35.0%) | . | 78/223 (35.0%) | 80/226 (35.4%) | 158/449 (35.2%) | . |
| RCA culprit | | | | 0.8905 | | | | 0.2293 |
| No | 346/528 (65.5%) | 338/519 (65.1%) | 684/1047 (65.3%) | . | 170/223 (76.2%) | 161/226 (71.2%) | 331/449 (73.7%) | . |
| Yes | 182/528 (34.5%) | 181/519 (34.9%) | 363/1047 (34.7%) | . | 53/223 (23.8%) | 65/226 (28.8%) | 118/449 (26.3%) | . |
| LAD culprit | | | | 0.7769 | | | | 0.0156 |
| No | 319/528 (60.4%) | 318/519 (61.3%) | 637/1047 (60.8%) | . | 72/223 (32.3%) | 98/226 (43.4%) | 170/449 (37.9%) | . |
| Yes | 209/528 (39.6%) | 201/519 (38.7%) | 410/1047 (39.2%) | . | 151/223 (67.7%) | 128/226 (56.6%) | 279/449 (62.1%) | . |
| CX culprit | | | | 0.8723 | | | | 0.0069 |
| No | 397/528 (75.2%) | 388/519 (74.8%) | 785/1047 (75.0%) | . | 208/223 (93.3%) | 193/226 (85.4%) | 401/449 (89.3%) | . |
| Yes | 131/528 (24.8%) | 131/519 (25.2%) | 262/1047 (25.0%) | . | 15/223 (6.7%) | 33/226 (14.6%) | 48/449 (10.7%) | . |

| | European Sites | | | | Asian Sites | | | |
|-----------------------------|--------------------------|------------------------------|---------------------|------------|--------------------------|------------------------------|--------------------|------------|
| | 3 months DAPT (N=528) | 12 months DAPT (N=519) | Overall (N=1047) | P value | 3 months DAPT (N=223) | 12 months DAPT (N=226) | Overall (N=449) | P value |
| Hospital stay | | | | 0.9434 | | | | 0.7295 |
| | (n =527) | (n =518) | (n =1045) | . | (n =223) | (n =226) | (n =449) | . |
| Range | 0.00 - 15.00 | 0.00 - 24.00 | 0.00 - 24.00 | . | 0.00 - 61.00 | 0.00 - 18.00 | 0.00 - 61.00 | . |
| Median (Q1-Q3) | 2.00 (1.00- 4.00) | 2.00 (1.00- 4.00) | 2.00 (1.00- 4.00) | . | 2.00 (1.00- 3.00) | 2.00 (1.00- 3.00) | 2.00 (1.00- 3.00) | . |
| Mean ± SD | 2.61 ± 2.34 | 2.69 ± 2.69 | 2.65 ± 2.52 | . | 2.87 ± 4.59 | 2.55 ± 1.99 | 2.71 ± 3.53 | . |
| ECG at discharge | | | | 0.5918 | | | | 0.3087 |
| No | 121/525 (23.0%) | 112/517 (21.7%) | 233/1042 (22.4%) | . | 24/223 (10.8%) | 18/226 (8.0%) | 42/449 (9.4%) | . |
| Yes | 404/525 (77.0%) | 405/517 (78.3%) | 809/1042 (77.6%) | . | 199/223 (89.2%) | 208/226 (92.0%) | 407/449 (90.6%) | . |
| Angina status at discharge | | | | 0.0511 | | | | 0.8219 |
| No angina | 522/527 (99.1%) | 517/518 (99.8%) | 1039/1045 (99.4%) | . | 203/223 (91.0%) | 209/226 (92.5%) | 412/449 (91.8%) | . |
| Stable angina | 0/527 (0.0%) | 1/518 (0.2%) | 1/1045 (0.1%) | . | 17/223 (7.6%) | 15/226 (6.6%) | 32/449 (7.1%) | . |
| Unstable angina | 5/527 (0.9%) | 0/518 (0.0%) | 5/1045 (0.5%) | . | 3/223 (1.3%) | 2/226 (0.9%) | 5/449 (1.1%) | . |
| Use of medication discharge | | | | 0.6243 | | | | 0.2461 |
| No | 3/527 (0.6%) | 1/518 (0.2%) | 4/1045 (0.4%) | . | 2/223 (0.9%) | 0/226 (0.0%) | 2/449 (0.4%) | . |
| Yes | 524/527 (99.4%) | 517/518 (99.8%) | 1041/1045 (99.6%) | . | 221/223 (99.1%) | 226/226 (100.0%) | 447/449 (99.6%) | . |
| Statin | | | | 0.2574 | | | | 0.5006 |
| No | 26/527 (4.9%) | 34/518 (6.6%) | 60/1045 (5.7%) | . | 8/223 (3.6%) | 11/226 (4.9%) | 19/449 (4.2%) | . |
| Yes | 501/527 (95.1%) | 484/518 (93.4%) | 985/1045 (94.3%) | . | 215/223 (96.4%) | 215/226 (95.1%) | 430/449 (95.8%) | . |
| Calcium antagonist | | | | 0.3792 | | | | 0.9637 |
| No | 450/527 (85.4%) | 452/518 (87.3%) | 902/1045 (86.3%) | . | 202/223 (90.6%) | 205/226 (90.7%) | 407/449 (90.6%) | . |
| Yes | 77/527 (14.6%) | 66/518 (12.7%) | 143/1045 (13.7%) | . | 21/223 (9.4%) | 21/226 (9.3%) | 42/449 (9.4%) | . |
| Beta blocker | | | | 0.2217 | | | | 0.8819 |
| No | 81/527 (15.4%) | 66/518 (12.7%) | 147/1045 (14.1%) | . | 50/223 (22.4%) | 52/226 (23.0%) | 102/449 (22.7%) | . |
| Yes | 446/527 (84.6%) | 452/518 (87.3%) | 898/1045 (85.9%) | . | 173/223 (77.6%) | 174/226 (77.0%) | 347/449 (77.3%) | . |
| Nitrate | | | | 0.8177 | | | | 0.8826 |
| No | 412/527 (78.2%) | 408/518 (78.8%) | 820/1045 (78.5%) | . | 117/223 (52.5%) | 117/226 (51.8%) | 234/449 (52.1%) | . |

| | European Sites | | | | Asian Sites | | | |
|----------------------------|--------------------------|------------------------------|---------------------|------------|--------------------------|------------------------------|--------------------|------------|
| | 3 months DAPT (N=528) | 12 months DAPT (N=519) | Overall (N=1047) | P value | 3 months DAPT (N=223) | 12 months DAPT (N=226) | Overall (N=449) | P value |
| Yes | 115/527 (21.8%) | 110/518 (21.2%) | 225/1045 (21.5%) | . | 106/223 (47.5%) | 109/226 (48.2%) | 215/449 (47.9%) | . |
| ACE-inhibitor | | | | 0.6365 | | | | 0.3701 |
| No | 196/527 (37.2%) | 200/518 (38.6%) | 396/1045 (37.9%) | . | 82/223 (36.8%) | 74/226 (32.7%) | 156/449 (34.7%) | . |
| Yes | 331/527 (62.8%) | 318/518 (61.4%) | 649/1045 (62.1%) | . | 141/223 (63.2%) | 152/226 (67.3%) | 293/449 (65.3%) | . |
| Digoxin | | | | 1.0000 | | | | 0.4967 |
| No | 525/527 (99.6%) | 516/518 (99.6%) | 1041/1045 (99.6%) | . | 222/223 (99.6%) | 226/226 (100.0%) | 448/449 (99.8%) | . |
| Yes | 2/527 (0.4%) | 2/518 (0.4%) | 4/1045 (0.4%) | . | 1/223 (0.4%) | 0/226 (0.0%) | 1/449 (0.2%) | . |
| Diuretics | | | | 0.2281 | | | | 0.9125 |
| No | 444/527 (84.3%) | 450/518 (86.9%) | 894/1045 (85.6%) | . | 201/223 (90.1%) | 203/226 (89.8%) | 404/449 (90.0%) | . |
| Yes | 83/527 (15.7%) | 68/518 (13.1%) | 151/1045 (14.4%) | . | 22/223 (9.9%) | 23/226 (10.2%) | 45/449 (10.0%) | . |
| Spironolacton | | | | 0.1696 | | | | 0.1580 |
| No | 511/527 (97.0%) | 509/518 (98.3%) | 1020/1045 (97.6%) | . | 194/223 (87.0%) | 206/226 (91.2%) | 400/449 (89.1%) | . |
| Yes | 16/527 (3.0%) | 9/518 (1.7%) | 25/1045 (2.4%) | . | 29/223 (13.0%) | 20/226 (8.8%) | 49/449 (10.9%) | . |
| A II blocker | | | | 0.9134 | | | | 0.6911 |
| No | 472/527 (89.6%) | 465/518 (89.8%) | 937/1045 (89.7%) | . | 205/223 (91.9%) | 210/226 (92.9%) | 415/449 (92.4%) | . |
| Yes | 55/527 (10.4%) | 53/518 (10.2%) | 108/1045 (10.3%) | . | 18/223 (8.1%) | 16/226 (7.1%) | 34/449 (7.6%) | . |
| Oral anticoagulant or NOAC | | | | 0.5343 | | | | 0.9869 |
| No | 515/527 (97.7%) | 509/518 (98.3%) | 1024/1045 (98.0%) | . | 220/223 (98.7%) | 223/226 (98.7%) | 443/449 (98.7%) | . |
| Yes | 12/527 (2.3%) | 9/518 (1.7%) | 21/1045 (2.0%) | . | 3/223 (1.3%) | 3/226 (1.3%) | 6/449 (1.3%) | . |
| Insulin | | | | 0.7325 | | | | 0.1880 |
| No | 497/527 (94.3%) | 491/518 (94.8%) | 988/1045 (94.5%) | . | 197/223 (88.3%) | 208/226 (92.0%) | 405/449 (90.2%) | . |
| Yes | 30/527 (5.7%) | 27/518 (5.2%) | 57/1045 (5.5%) | . | 26/223 (11.7%) | 18/226 (8.0%) | 44/449 (9.8%) | . |
| Oral anti diabetic | | | | 0.4330 | | | | 0.6443 |
| No | 464/527 (88.0%) | 464/518 (89.6%) | 928/1045 (88.8%) | . | 169/223 (75.8%) | 167/226 (73.9%) | 336/449 (74.8%) | . |
| Yes | 63/527 (12.0%) | 54/518 (10.4%) | 117/1045 (11.2%) | . | 54/223 (24.2%) | 59/226 (26.1%) | 113/449 (25.2%) | . |
| Proton pump inhibitor | | | | 0.9873 | | | | 0.6514 |

| | European Sites | | | | Asian Sites | | | |
|----------------------------|--------------------------|------------------------------|---------------------|------------|--------------------------|------------------------------|--------------------|------------|
| | 3 months DAPT (N=528) | 12 months DAPT (N=519) | Overall (N=1047) | P value | 3 months DAPT (N=223) | 12 months DAPT (N=226) | Overall (N=449) | P value |
| No | 190/527 (36.1%) | 187/518 (36.1%) | 377/1045 (36.1%) | . | 131/223 (58.7%) | 128/226 (56.6%) | 259/449 (57.7%) | . |
| Yes | 337/527 (63.9%) | 331/518 (63.9%) | 668/1045 (63.9%) | . | 92/223 (41.3%) | 98/226 (43.4%) | 190/449 (42.3%) | . |
| Other medication discharge | | | | 0.8987 | | | | 0.1603 |
| No | 291/527 (55.2%) | 284/518 (54.8%) | 575/1045 (55.0%) | . | 135/223 (60.5%) | 122/226 (54.0%) | 257/449 (57.2%) | . |
| Yes | 236/527 (44.8%) | 234/518 (45.2%) | 470/1045 (45.0%) | . | 88/223 (39.5%) | 104/226 (46.0%) | 192/449 (42.8%) | . |

Table 1.4 Follow Up 90 days

| | European Sites | | | | Asian Sites | | | |
|--|-----------------------|------------------------|-------------------|---------|-----------------------|------------------------|------------------|---------|
| | 3 months DAPT (N=521) | 12 months DAPT (N=516) | Overall (N=1037) | P value | 3 months DAPT (N=223) | 12 months DAPT (N=226) | Overall (N=449) | P value |
| All cause mortality, MI, Stent thrombosis, Stroke, TVR or Bleeding (BARC II, III, V) | | | | 0.8256 | | | | 0.6901 |
| No | 508/521 (97.5%) | 502/516 (97.3%) | 1010/1037 (97.4%) | . | 219/223 (98.2%) | 223/226 (98.7%) | 442/449 (98.4%) | . |
| Yes | 13/521 (2.5%) | 14/516 (2.7%) | 27/1037 (2.6%) | . | 4/223 (1.8%) | 3/226 (1.3%) | 7/449 (1.6%) | . |
| All cause mortality within 90 days | | | | 1.0000 | | | | 1.0000 |
| No | 519/521 (99.6%) | 515/516 (99.8%) | 1034/1037 (99.7%) | . | 222/223 (99.6%) | 225/226 (99.6%) | 447/449 (99.6%) | . |
| Yes | 2/521 (0.4%) | 1/516 (0.2%) | 3/1037 (0.3%) | . | 1/223 (0.4%) | 1/226 (0.4%) | 2/449 (0.4%) | . |
| Cardiac mortality within 90 days | | | | 0.4995 | | | | 1.0000 |
| No | 519/521 (99.6%) | 516/516 (100.0%) | 1035/1037 (99.8%) | . | 223/223 (100.0%) | 225/226 (99.6%) | 448/449 (99.8%) | . |
| Yes | 2/521 (0.4%) | 0/516 (0.0%) | 2/1037 (0.2%) | . | 0/223 (0.0%) | 1/226 (0.4%) | 1/449 (0.2%) | . |
| Stent thrombosis within 90 days | | | | 1.0000 | | | | 0.4967 |
| No | 518/521 (99.4%) | 514/516 (99.6%) | 1032/1037 (99.5%) | . | 222/223 (99.6%) | 226/226 (100.0%) | 448/449 (99.8%) | . |
| Yes | 3/521 (0.6%) | 2/516 (0.4%) | 5/1037 (0.5%) | . | 1/223 (0.4%) | 0/226 (0.0%) | 1/449 (0.2%) | . |
| Definite Stent thrombosis within 90 days | | | | 0.6228 | | | | 0.4967 |
| No | 520/521 (99.8%) | 514/516 (99.6%) | 1034/1037 (99.7%) | . | 222/223 (99.6%) | 226/226 (100.0%) | 448/449 (99.8%) | . |
| Yes | 1/521 (0.2%) | 2/516 (0.4%) | 3/1037 (0.3%) | . | 1/223 (0.4%) | 0/226 (0.0%) | 1/449 (0.2%) | . |
| Probable Stent thrombosis within 90 days | | | | 1.0000 | | | | . |
| No | 520/521 (99.8%) | 516/516 (100.0%) | 1036/1037 (99.9%) | . | 223/223 (100.0%) | 226/226 (100.0%) | 449/449 (100.0%) | . |
| Yes | 1/521 (0.2%) | 0/516 (0.0%) | 1/1037 (0.1%) | . | 0/223 (0.0%) | 0/226 (0.0%) | 0/449 (0.0%) | . |
| Possible Stent thrombosis within 90 days | | | | 1.0000 | | | | . |
| No | 520/521 (99.8%) | 516/516 (100.0%) | 1036/1037 (99.9%) | . | 223/223 (100.0%) | 226/226 (100.0%) | 449/449 (100.0%) | . |
| Yes | 1/521 (0.2%) | 0/516 (0.0%) | 1/1037 (0.1%) | . | 0/223 (0.0%) | 0/226 (0.0%) | 0/449 (0.0%) | . |
| Definite/Probable Stent thrombosis within 90 days | | | | 1.0000 | | | | 0.4967 |

| | European Sites | | | | Asian Sites | | | |
|--|-----------------------|------------------------|-------------------|---------|-----------------------|------------------------|-----------------|---------|
| | 3 months DAPT (N=521) | 12 months DAPT (N=516) | Overall (N=1037) | P value | 3 months DAPT (N=223) | 12 months DAPT (N=226) | Overall (N=449) | P value |
| No | 519/521 (99.6%) | 514/516 (99.6%) | 1033/1037 (99.6%) | . | 222/223 (99.6%) | 226/226 (100.0%) | 448/449 (99.8%) | . |
| Yes | 2/521 (0.4%) | 2/516 (0.4%) | 4/1037 (0.4%) | . | 1/223 (0.4%) | 0/226 (0.0%) | 1/449 (0.2%) | . |
| Stent thrombosis and/or cardiac mortality within 90 days | | | | 1.0000 | | | | 1.0000 |
| No | 518/521 (99.4%) | 514/516 (99.6%) | 1032/1037 (99.5%) | . | 222/223 (99.6%) | 225/226 (99.6%) | 447/449 (99.6%) | . |
| Yes | 3/521 (0.6%) | 2/516 (0.4%) | 5/1037 (0.5%) | . | 1/223 (0.4%) | 1/226 (0.4%) | 2/449 (0.4%) | . |
| Target vessel revascularisation within 90 days | | | | 0.4516 | | | | 0.4967 |
| No | 516/521 (99.0%) | 514/516 (99.6%) | 1030/1037 (99.3%) | . | 222/223 (99.6%) | 226/226 (100.0%) | 448/449 (99.8%) | . |
| Yes | 5/521 (1.0%) | 2/516 (0.4%) | 7/1037 (0.7%) | . | 1/223 (0.4%) | 0/226 (0.0%) | 1/449 (0.2%) | . |
| Any bleeding within 90 days | | | | 0.8300 | | | | 0.7165 |
| No | 507/521 (97.3%) | 501/516 (97.1%) | 1008/1037 (97.2%) | . | 220/223 (98.7%) | 222/226 (98.2%) | 442/449 (98.4%) | . |
| Yes | 14/521 (2.7%) | 15/516 (2.9%) | 29/1037 (2.8%) | . | 3/223 (1.3%) | 4/226 (1.8%) | 7/449 (1.6%) | . |
| Bleeding Barc II, III or V within 90 days | | | | 0.5502 | | | | 0.5546 |
| No | 516/521 (99.0%) | 509/516 (98.6%) | 1025/1037 (98.8%) | . | 221/223 (99.1%) | 225/226 (99.6%) | 446/449 (99.3%) | . |
| Yes | 5/521 (1.0%) | 7/516 (1.4%) | 12/1037 (1.2%) | . | 2/223 (0.9%) | 1/226 (0.4%) | 3/449 (0.7%) | . |
| Stroke within 90 days | | | | 0.4976 | | | | 1.0000 |
| No | 521/521 (100.0%) | 515/516 (99.8%) | 1036/1037 (99.9%) | . | 222/223 (99.6%) | 225/226 (99.6%) | 447/449 (99.6%) | . |
| Yes | 0/521 (0.0%) | 1/516 (0.2%) | 1/1037 (0.1%) | . | 1/223 (0.4%) | 1/226 (0.4%) | 2/449 (0.4%) | . |
| Ischemic stroke within 90 days | | | | 0.4976 | | | | 1.0000 |
| No | 521/521 (100.0%) | 515/516 (99.8%) | 1036/1037 (99.9%) | . | 222/223 (99.6%) | 225/226 (99.6%) | 447/449 (99.6%) | . |
| Yes | 0/521 (0.0%) | 1/516 (0.2%) | 1/1037 (0.1%) | . | 1/223 (0.4%) | 1/226 (0.4%) | 2/449 (0.4%) | . |
| MI within 90 days | | | | 0.4497 | | | | 0.4967 |

| | European Sites | | | | Asian Sites | | | |
|-----|-----------------------|------------------------|-------------------|---------|-----------------------|------------------------|-----------------|---------|
| | 3 months DAPT (N=521) | 12 months DAPT (N=516) | Overall (N=1037) | P value | 3 months DAPT (N=223) | 12 months DAPT (N=226) | Overall (N=449) | P value |
| No | 519/521 (99.6%) | 512/516 (99.2%) | 1031/1037 (99.4%) | . | 222/223 (99.6%) | 226/226 (100.0%) | 448/449 (99.8%) | . |
| Yes | 2/521 (0.4%) | 4/516 (0.8%) | 6/1037 (0.6%) | . | 1/223 (0.4%) | 0/226 (0.0%) | 1/449 (0.2%) | . |

| | European Sites | | | | Asian Sites | | | |
|--|-----------------------|------------------------|-------------------|---------|-----------------------|------------------------|------------------|---------|
| | 3 months DAPT (N=518) | 12 months DAPT (N=514) | Overall (N=1032) | P value | 3 months DAPT (N=223) | 12 months DAPT (N=225) | Overall (N=448) | P value |
| All cause mortality, MI, Stent thrombosis, Stroke, TVR or Bleeding (BARC II, III, V) | | | | 0.6935 | | | | 0.2356 |
| No | 490/518 (94.6%) | 489/514 (95.1%) | 979/1032 (94.9%) | . | 215/223 (96.4%) | 221/225 (98.2%) | 436/448 (97.3%) | . |
| Yes | 28/518 (5.4%) | 25/514 (4.9%) | 53/1032 (5.1%) | . | 8/223 (3.6%) | 4/225 (1.8%) | 12/448 (2.7%) | . |
| All cause mortality within 180 days | | | | 0.6866 | | | | 0.6225 |
| No | 514/518 (99.2%) | 512/514 (99.6%) | 1026/1032 (99.4%) | . | 221/223 (99.1%) | 224/225 (99.6%) | 445/448 (99.3%) | . |
| Yes | 4/518 (0.8%) | 2/514 (0.4%) | 6/1032 (0.6%) | . | 2/223 (0.9%) | 1/225 (0.4%) | 3/448 (0.7%) | . |
| Cardiac mortality within 180 days | | | | 0.2493 | | | | 1.0000 |
| No | 515/518 (99.4%) | 514/514 (100.0%) | 1029/1032 (99.7%) | . | 223/223 (100.0%) | 224/225 (99.6%) | 447/448 (99.8%) | . |
| Yes | 3/518 (0.6%) | 0/514 (0.0%) | 3/1032 (0.3%) | . | 0/223 (0.0%) | 1/225 (0.4%) | 1/448 (0.2%) | . |
| Stent thrombosis within 180 days | | | | 0.0964 | | | | 0.1545 |
| No | 511/518 (98.6%) | 512/514 (99.6%) | 1023/1032 (99.1%) | . | 221/223 (99.1%) | 225/225 (100.0%) | 446/448 (99.6%) | . |
| Yes | 7/518 (1.4%) | 2/514 (0.4%) | 9/1032 (0.9%) | . | 2/223 (0.9%) | 0/225 (0.0%) | 2/448 (0.4%) | . |
| Definite Stent thrombosis within 180 days | | | | 1.0000 | | | | 0.4978 |
| No | 515/518 (99.4%) | 512/514 (99.6%) | 1027/1032 (99.5%) | . | 222/223 (99.6%) | 225/225 (100.0%) | 447/448 (99.8%) | . |
| Yes | 3/518 (0.6%) | 2/514 (0.4%) | 5/1032 (0.5%) | . | 1/223 (0.4%) | 0/225 (0.0%) | 1/448 (0.2%) | . |
| Probable Stent thrombosis within 180 days | | | | 0.4995 | | | | 0.4978 |
| No | 516/518 (99.6%) | 514/514 (100.0%) | 1030/1032 (99.8%) | . | 222/223 (99.6%) | 225/225 (100.0%) | 447/448 (99.8%) | . |
| Yes | 2/518 (0.4%) | 0/514 (0.0%) | 2/1032 (0.2%) | . | 1/223 (0.4%) | 0/225 (0.0%) | 1/448 (0.2%) | . |
| Possible Stent thrombosis within 180 days | | | | 0.4995 | | | | . |
| No | 516/518 (99.6%) | 514/514 (100.0%) | 1030/1032 (99.8%) | . | 223/223 (100.0%) | 225/225 (100.0%) | 448/448 (100.0%) | . |
| Yes | 2/518 (0.4%) | 0/514 (0.0%) | 2/1032 (0.2%) | . | 0/223 (0.0%) | 0/225 (0.0%) | 0/448 (0.0%) | . |
| Definite/Probable Stent thrombosis within 180 days | | | | 0.2595 | | | | 0.1545 |

| | European Sites | | | | Asian Sites | | | |
|---|-----------------------|------------------------|-------------------|---------|-----------------------|------------------------|-----------------|---------|
| | 3 months DAPT (N=518) | 12 months DAPT (N=514) | Overall (N=1032) | P value | 3 months DAPT (N=223) | 12 months DAPT (N=225) | Overall (N=448) | P value |
| No | 513/518 (99.0%) | 512/514 (99.6%) | 1025/1032 (99.3%) | . | 221/223 (99.1%) | 225/225 (100.0%) | 446/448 (99.6%) | . |
| Yes | 5/518 (1.0%) | 2/514 (0.4%) | 7/1032 (0.7%) | . | 2/223 (0.9%) | 0/225 (0.0%) | 2/448 (0.4%) | . |
| Stent thrombosis and/or cardiac mortality within 180 days | | | | 0.0964 | | | | 0.5572 |
| No | 511/518 (98.6%) | 512/514 (99.6%) | 1023/1032 (99.1%) | . | 221/223 (99.1%) | 224/225 (99.6%) | 445/448 (99.3%) | . |
| Yes | 7/518 (1.4%) | 2/514 (0.4%) | 9/1032 (0.9%) | . | 2/223 (0.9%) | 1/225 (0.4%) | 3/448 (0.7%) | . |
| Target vessel revascularisation within 180 days | | | | 0.4980 | | | | 0.0809 |
| No | 507/518 (97.9%) | 506/514 (98.4%) | 1013/1032 (98.2%) | . | 220/223 (98.7%) | 225/225 (100.0%) | 445/448 (99.3%) | . |
| Yes | 11/518 (2.1%) | 8/514 (1.6%) | 19/1032 (1.8%) | . | 3/223 (1.3%) | 0/225 (0.0%) | 3/448 (0.7%) | . |
| Any bleeding within 180 days | | | | 0.8934 | | | | 0.7465 |
| No | 497/518 (95.9%) | 494/514 (96.1%) | 991/1032 (96.0%) | . | 219/223 (98.2%) | 220/225 (97.8%) | 439/448 (98.0%) | . |
| Yes | 21/518 (4.1%) | 20/514 (3.9%) | 41/1032 (4.0%) | . | 4/223 (1.8%) | 5/225 (2.2%) | 9/448 (2.0%) | . |
| Bleeding Barc II, III or V within 180 days | | | | 0.9853 | | | | 0.6457 |
| No | 507/518 (97.9%) | 503/514 (97.9%) | 1010/1032 (97.9%) | . | 220/223 (98.7%) | 223/225 (99.1%) | 443/448 (98.9%) | . |
| Yes | 11/518 (2.1%) | 11/514 (2.1%) | 22/1032 (2.1%) | . | 3/223 (1.3%) | 2/225 (0.9%) | 5/448 (1.1%) | . |
| Stroke within 180 days | | | | 0.4981 | | | | 1.0000 |
| No | 518/518 (100.0%) | 513/514 (99.8%) | 1031/1032 (99.9%) | . | 222/223 (99.6%) | 224/225 (99.6%) | 446/448 (99.6%) | . |
| Yes | 0/518 (0.0%) | 1/514 (0.2%) | 1/1032 (0.1%) | . | 1/223 (0.4%) | 1/225 (0.4%) | 2/448 (0.4%) | . |
| Ischemic stroke within 180 days | | | | 0.4981 | | | | 1.0000 |
| No | 518/518 (100.0%) | 513/514 (99.8%) | 1031/1032 (99.9%) | . | 222/223 (99.6%) | 224/225 (99.6%) | 446/448 (99.6%) | . |
| Yes | 0/518 (0.0%) | 1/514 (0.2%) | 1/1032 (0.1%) | . | 1/223 (0.4%) | 1/225 (0.4%) | 2/448 (0.4%) | . |
| MI within 180 days | | | | 0.7910 | | | | 0.0809 |

| | European Sites | | | | Asian Sites | | | |
|-----|-----------------------|------------------------|-------------------|---------|-----------------------|------------------------|-----------------|---------|
| | 3 months DAPT (N=518) | 12 months DAPT (N=514) | Overall (N=1032) | P value | 3 months DAPT (N=223) | 12 months DAPT (N=225) | Overall (N=448) | P value |
| No | 511/518 (98.6%) | 508/514 (98.8%) | 1019/1032 (98.7%) | . | 220/223 (98.7%) | 225/225 (100.0%) | 445/448 (99.3%) | . |
| Yes | 7/518 (1.4%) | 6/514 (1.2%) | 13/1032 (1.3%) | . | 3/223 (1.3%) | 0/225 (0.0%) | 3/448 (0.7%) | . |

Table 1.6 Follow Up 360 days

| | European Sites | | | | Asian Sites | | | |
|--|-----------------------|------------------------|-------------------|---------|-----------------------|------------------------|-----------------|---------|
| | 3 months DAPT (N=518) | 12 months DAPT (N=512) | Overall (N=1030) | P value | 3 months DAPT (N=223) | 12 months DAPT (N=225) | Overall (N=448) | P value |
| All cause mortality, MI, Stent thrombosis, Stroke, TVR or Bleeding (BARC II, III, V) | | | | 0.7817 | | | | 0.8726 |
| No | 473/518 (91.3%) | 465/512 (90.8%) | 938/1030 (91.1%) | . | 208/223 (93.3%) | 209/225 (92.9%) | 417/448 (93.1%) | . |
| Yes | 45/518 (8.7%) | 47/512 (9.2%) | 92/1030 (8.9%) | . | 15/223 (6.7%) | 16/225 (7.1%) | 31/448 (6.9%) | . |
| All cause mortality within 360 days | | | | 0.0851 | | | | 0.4677 |
| No | 509/518 (98.3%) | 509/512 (99.4%) | 1018/1030 (98.8%) | . | 218/223 (97.8%) | 222/225 (98.7%) | 440/448 (98.2%) | . |
| Yes | 9/518 (1.7%) | 3/512 (0.6%) | 12/1030 (1.2%) | . | 5/223 (2.2%) | 3/225 (1.3%) | 8/448 (1.8%) | . |
| Cardiac mortality within 360 days | | | | 0.1045 | | | | 0.6457 |
| No | 513/518 (99.0%) | 511/512 (99.8%) | 1024/1030 (99.4%) | . | 220/223 (98.7%) | 223/225 (99.1%) | 443/448 (98.9%) | . |
| Yes | 5/518 (1.0%) | 1/512 (0.2%) | 6/1030 (0.6%) | . | 3/223 (1.3%) | 2/225 (0.9%) | 5/448 (1.1%) | . |
| Definite Stent thrombosis within 360 days | | | | 0.6866 | | | | 0.6225 |
| No | 514/518 (99.2%) | 510/512 (99.6%) | 1024/1030 (99.4%) | . | 221/223 (99.1%) | 224/225 (99.6%) | 445/448 (99.3%) | . |
| Yes | 4/518 (0.8%) | 2/512 (0.4%) | 6/1030 (0.6%) | . | 2/223 (0.9%) | 1/225 (0.4%) | 3/448 (0.7%) | . |
| Probable Stent thrombosis within 360 days | | | | 0.4995 | | | | 0.4978 |
| No | 516/518 (99.6%) | 512/512 (100.0%) | 1028/1030 (99.8%) | . | 222/223 (99.6%) | 225/225 (100.0%) | 447/448 (99.8%) | . |
| Yes | 2/518 (0.4%) | 0/512 (0.0%) | 2/1030 (0.2%) | . | 1/223 (0.4%) | 0/225 (0.0%) | 1/448 (0.2%) | . |
| Possible Stent thrombosis within 360 days | | | | 0.4995 | | | | 1.0000 |
| No | 516/518 (99.6%) | 512/512 (100.0%) | 1028/1030 (99.8%) | . | 222/223 (99.6%) | 224/225 (99.6%) | 446/448 (99.6%) | . |
| Yes | 2/518 (0.4%) | 0/512 (0.0%) | 2/1030 (0.2%) | . | 1/223 (0.4%) | 1/225 (0.4%) | 2/448 (0.4%) | . |
| Definite/Probable Stent thrombosis within 360 days | | | | 0.1606 | | | | 0.3108 |
| No | 512/518 (98.8%) | 510/512 (99.6%) | 1022/1030 (99.2%) | . | 220/223 (98.7%) | 224/225 (99.6%) | 444/448 (99.1%) | . |
| Yes | 6/518 (1.2%) | 2/512 (0.4%) | 8/1030 (0.8%) | . | 3/223 (1.3%) | 1/225 (0.4%) | 4/448 (0.9%) | . |
| Stent thrombosis and/or cardiac mortality within 360 days | | | | 0.0533 | | | | 0.3060 |

| | European Sites | | | | Asian Sites | | | |
|--|-----------------------|------------------------|-------------------|---------|-----------------------|------------------------|-----------------|---------|
| | 3 months DAPT (N=518) | 12 months DAPT (N=512) | Overall (N=1030) | P value | 3 months DAPT (N=223) | 12 months DAPT (N=225) | Overall (N=448) | P value |
| No | 508/518 (98.1%) | 509/512 (99.4%) | 1017/1030 (98.7%) | . | 217/223 (97.3%) | 222/225 (98.7%) | 439/448 (98.0%) | . |
| Yes | 10/518 (1.9%) | 3/512 (0.6%) | 13/1030 (1.3%) | . | 6/223 (2.7%) | 3/225 (1.3%) | 9/448 (2.0%) | . |
| Target vessel revascularisation within 360 days | | | | 0.7187 | | | | 0.9886 |
| No | 499/518 (96.3%) | 491/512 (95.9%) | 990/1030 (96.1%) | . | 218/223 (97.8%) | 220/225 (97.8%) | 438/448 (97.8%) | . |
| Yes | 19/518 (3.7%) | 21/512 (4.1%) | 40/1030 (3.9%) | . | 5/223 (2.2%) | 5/225 (2.2%) | 10/448 (2.2%) | . |
| Any bleeding within 360 days | | | | 0.7397 | | | | 0.0869 |
| No | 494/518 (95.4%) | 486/512 (94.9%) | 980/1030 (95.1%) | . | 218/223 (97.8%) | 213/225 (94.7%) | 431/448 (96.2%) | . |
| Yes | 24/518 (4.6%) | 26/512 (5.1%) | 50/1030 (4.9%) | . | 5/223 (2.2%) | 12/225 (5.3%) | 17/448 (3.8%) | . |
| Bleeding Barc II, III or V within 360 days | | | | 0.8257 | | | | 0.3677 |
| No | 504/518 (97.3%) | 497/512 (97.1%) | 1001/1030 (97.2%) | . | 219/223 (98.2%) | 218/225 (96.9%) | 437/448 (97.5%) | . |
| Yes | 14/518 (2.7%) | 15/512 (2.9%) | 29/1030 (2.8%) | . | 4/223 (1.8%) | 7/225 (3.1%) | 11/448 (2.5%) | . |
| Stroke within 360 days | | | | 0.6225 | | | | 1.0000 |
| No | 517/518 (99.8%) | 510/512 (99.6%) | 1027/1030 (99.7%) | . | 222/223 (99.6%) | 224/225 (99.6%) | 446/448 (99.6%) | . |
| Yes | 1/518 (0.2%) | 2/512 (0.4%) | 3/1030 (0.3%) | . | 1/223 (0.4%) | 1/225 (0.4%) | 2/448 (0.4%) | . |
| Ischemic stroke within 360 days | | | | 0.6225 | | | | 1.0000 |
| No | 517/518 (99.8%) | 510/512 (99.6%) | 1027/1030 (99.7%) | . | 222/223 (99.6%) | 224/225 (99.6%) | 446/448 (99.6%) | . |
| Yes | 1/518 (0.2%) | 2/512 (0.4%) | 3/1030 (0.3%) | . | 1/223 (0.4%) | 1/225 (0.4%) | 2/448 (0.4%) | . |
| MI within 360 days | | | | 0.6465 | | | | 0.0897 |
| No | 508/518 (98.1%) | 500/512 (97.7%) | 1008/1030 (97.9%) | . | 216/223 (96.9%) | 223/225 (99.1%) | 439/448 (98.0%) | . |
| Yes | 10/518 (1.9%) | 12/512 (2.3%) | 22/1030 (2.1%) | . | 7/223 (3.1%) | 2/225 (0.9%) | 9/448 (2.0%) | . |
| Combined incidence of Death, MI, Stent Thrombosis, Stroke or TVR | | | | 0.7616 | | | | 0.8069 |
| No | 486/518 (93.8%) | 478/512 (93.4%) | 964/1030 (93.6%) | . | 212/223 (95.1%) | 215/225 (95.6%) | 427/448 (95.3%) | . |
| Yes | 32/518 (6.2%) | 34/512 (6.6%) | 66/1030 (6.4%) | . | 11/223 (4.9%) | 10/225 (4.4%) | 21/448 (4.7%) | . |

| | European Sites | | | | Asian Sites | | | |
|-----------------------------------|-----------------------|------------------------|------------------|---------|-----------------------|------------------------|-----------------|---------|
| | 3 months DAPT (N=518) | 12 months DAPT (N=512) | Overall (N=1030) | P value | 3 months DAPT (N=223) | 12 months DAPT (N=225) | Overall (N=448) | P value |
| Revascularization within 360 days | | | | 0.3611 | | | | 0.7716 |
| No | 477/518 (92.1%) | 479/512 (93.6%) | 956/1030 (92.8%) | . | 218/223 (97.8%) | 219/225 (97.3%) | 437/448 (97.5%) | . |
| Yes | 41/518 (7.9%) | 33/512 (6.4%) | 74/1030 (7.2%) | . | 5/223 (2.2%) | 6/225 (2.7%) | 11/448 (2.5%) | . |

Table 1.7 Follow Up 720 days

| | European Sites | | | | Asian Sites | | | |
|--|-----------------------|------------------------|-------------------|---------|-----------------------|------------------------|-----------------|---------|
| | 3 months DAPT (N=510) | 12 months DAPT (N=505) | Overall (N=1015) | P value | 3 months DAPT (N=223) | 12 months DAPT (N=222) | Overall (N=445) | P value |
| All cause mortality, MI, Stent thrombosis, Stroke, TVR or Bleeding (BARC II, III, V) | | | | 0.8998 | | | | 0.4039 |
| No | 443/510 (86.9%) | 440/505 (87.1%) | 883/1015 (87.0%) | . | 205/223 (91.9%) | 199/222 (89.6%) | 404/445 (90.8%) | . |
| Yes | 67/510 (13.1%) | 65/505 (12.9%) | 132/1015 (13.0%) | . | 18/223 (8.1%) | 23/222 (10.4%) | 41/445 (9.2%) | . |
| All cause mortality within 720 days | | | | 0.5760 | | | | 0.2450 |
| No | 495/510 (97.1%) | 493/505 (97.6%) | 988/1015 (97.3%) | . | 215/223 (96.4%) | 218/222 (98.2%) | 433/445 (97.3%) | . |
| Yes | 15/510 (2.9%) | 12/505 (2.4%) | 27/1015 (2.7%) | . | 8/223 (3.6%) | 4/222 (1.8%) | 12/445 (2.7%) | . |
| Cardiac mortality within 720 days | | | | 0.4125 | | | | 0.4795 |
| No | 502/510 (98.4%) | 500/505 (99.0%) | 1002/1015 (98.7%) | . | 218/223 (97.8%) | 219/222 (98.6%) | 437/445 (98.2%) | . |
| Yes | 8/510 (1.6%) | 5/505 (1.0%) | 13/1015 (1.3%) | . | 5/223 (2.2%) | 3/222 (1.4%) | 8/445 (1.8%) | . |
| Definite Stent thrombosis within 720 days | | | | 1.0000 | | | | 1.0000 |
| No | 505/510 (99.0%) | 500/505 (99.0%) | 1005/1015 (99.0%) | . | 221/223 (99.1%) | 221/222 (99.5%) | 442/445 (99.3%) | . |
| Yes | 5/510 (1.0%) | 5/505 (1.0%) | 10/1015 (1.0%) | . | 2/223 (0.9%) | 1/222 (0.5%) | 3/445 (0.7%) | . |
| Probable Stent thrombosis within 720 days | | | | 0.2493 | | | | 0.4989 |
| No | 507/510 (99.4%) | 505/505 (100.0%) | 1012/1015 (99.7%) | . | 221/223 (99.1%) | 222/222 (100.0%) | 443/445 (99.6%) | . |
| Yes | 3/510 (0.6%) | 0/505 (0.0%) | 3/1015 (0.3%) | . | 2/223 (0.9%) | 0/222 (0.0%) | 2/445 (0.4%) | . |
| Possible Stent thrombosis within 720 days | | | | 0.4995 | | | | 1.0000 |
| No | 508/510 (99.6%) | 505/505 (100.0%) | 1013/1015 (99.8%) | . | 222/223 (99.6%) | 221/222 (99.5%) | 443/445 (99.6%) | . |
| Yes | 2/510 (0.4%) | 0/505 (0.0%) | 2/1015 (0.2%) | . | 1/223 (0.4%) | 1/222 (0.5%) | 2/445 (0.4%) | . |
| Definite/Probable Stent thrombosis within 720 days | | | | 0.4125 | | | | 0.1789 |
| No | 502/510 (98.4%) | 500/505 (99.0%) | 1002/1015 (98.7%) | . | 219/223 (98.2%) | 221/222 (99.5%) | 440/445 (98.9%) | . |
| Yes | 8/510 (1.6%) | 5/505 (1.0%) | 13/1015 (1.3%) | . | 4/223 (1.8%) | 1/222 (0.5%) | 5/445 (1.1%) | . |
| All cause mortality and/or def/prob ST within 720 days | | | | 0.5284 | | | | 0.1289 |

| | European Sites | | | | Asian Sites | | | |
|--|-----------------------|------------------------|------------------|---------|-----------------------|------------------------|-----------------|---------|
| | 3 months DAPT (N=510) | 12 months DAPT (N=505) | Overall (N=1015) | P value | 3 months DAPT (N=223) | 12 months DAPT (N=222) | Overall (N=445) | P value |
| No | 489/510 (95.9%) | 488/505 (96.6%) | 977/1015 (96.3%) | . | 212/223 (95.1%) | 217/222 (97.7%) | 429/445 (96.4%) | . |
| Yes | 21/510 (4.1%) | 17/505 (3.4%) | 38/1015 (3.7%) | . | 11/223 (4.9%) | 5/222 (2.3%) | 16/445 (3.6%) | . |
| Stent thrombosis and/or cardiac mortality within 720 days | | | | 0.4226 | | | | 0.2450 |
| No | 496/510 (97.3%) | 495/505 (98.0%) | 991/1015 (97.6%) | . | 215/223 (96.4%) | 218/222 (98.2%) | 433/445 (97.3%) | . |
| Yes | 14/510 (2.7%) | 10/505 (2.0%) | 24/1015 (2.4%) | . | 8/223 (3.6%) | 4/222 (1.8%) | 12/445 (2.7%) | . |
| All cause mortality, Def/Prob ST, Stroke or MI within 720 days | | | | 0.8278 | | | | 0.6697 |
| No | 477/510 (93.5%) | 474/505 (93.9%) | 951/1015 (93.7%) | . | 211/223 (94.6%) | 212/222 (95.5%) | 423/445 (95.1%) | . |
| Yes | 33/510 (6.5%) | 31/505 (6.1%) | 64/1015 (6.3%) | . | 12/223 (5.4%) | 10/222 (4.5%) | 22/445 (4.9%) | . |
| All cause mortality, Def/Prob ST or MI within 720 days | | | | 0.7215 | | | | 0.3655 |
| No | 478/510 (93.7%) | 476/505 (94.3%) | 954/1015 (94.0%) | . | 211/223 (94.6%) | 214/222 (96.4%) | 425/445 (95.5%) | . |
| Yes | 32/510 (6.3%) | 29/505 (5.7%) | 61/1015 (6.0%) | . | 12/223 (5.4%) | 8/222 (3.6%) | 20/445 (4.5%) | . |
| Cardiac mortality or MI within 720 days | | | | 0.6862 | | | | 0.6170 |
| No | 484/510 (94.9%) | 482/505 (95.4%) | 966/1015 (95.2%) | . | 214/223 (96.0%) | 215/222 (96.8%) | 429/445 (96.4%) | . |
| Yes | 26/510 (5.1%) | 23/505 (4.6%) | 49/1015 (4.8%) | . | 9/223 (4.0%) | 7/222 (3.2%) | 16/445 (3.6%) | . |
| Target vessel revascularisation within 720 days | | | | 0.9219 | | | | 0.7846 |
| No | 481/510 (94.3%) | 477/505 (94.5%) | 958/1015 (94.4%) | . | 216/223 (96.9%) | 216/222 (97.3%) | 432/445 (97.1%) | . |
| Yes | 29/510 (5.7%) | 28/505 (5.5%) | 57/1015 (5.6%) | . | 7/223 (3.1%) | 6/222 (2.7%) | 13/445 (2.9%) | . |
| Any bleeding within 720 days | | | | 0.8625 | | | | 0.0431 |
| No | 481/510 (94.3%) | 475/505 (94.1%) | 956/1015 (94.2%) | . | 217/223 (97.3%) | 207/222 (93.2%) | 424/445 (95.3%) | . |
| Yes | 29/510 (5.7%) | 30/505 (5.9%) | 59/1015 (5.8%) | . | 6/223 (2.7%) | 15/222 (6.8%) | 21/445 (4.7%) | . |
| Bleeding Barc II, III or V within 720 days | | | | 0.9753 | | | | 0.1861 |
| No | 491/510 (96.3%) | 486/505 (96.2%) | 977/1015 (96.3%) | . | 218/223 (97.8%) | 212/222 (95.5%) | 430/445 (96.6%) | . |
| Yes | 19/510 (3.7%) | 19/505 (3.8%) | 38/1015 (3.7%) | . | 5/223 (2.2%) | 10/222 (4.5%) | 15/445 (3.4%) | . |

| | European Sites | | | | Asian Sites | | | |
|---|-----------------------|------------------------|-------------------|---------|-----------------------|------------------------|-----------------|---------|
| | 3 months DAPT (N=510) | 12 months DAPT (N=505) | Overall (N=1015) | P value | 3 months DAPT (N=223) | 12 months DAPT (N=222) | Overall (N=445) | P value |
| Stroke within 720 days | | | | 0.6228 | | | | 0.6233 |
| No | 509/510 (99.8%) | 503/505 (99.6%) | 1012/1015 (99.7%) | . | 222/223 (99.6%) | 220/222 (99.1%) | 442/445 (99.3%) | . |
| Yes | 1/510 (0.2%) | 2/505 (0.4%) | 3/1015 (0.3%) | . | 1/223 (0.4%) | 2/222 (0.9%) | 3/445 (0.7%) | . |
| Ischemic stroke within 720 days | | | | 0.6228 | | | | 0.6233 |
| No | 509/510 (99.8%) | 503/505 (99.6%) | 1012/1015 (99.7%) | . | 222/223 (99.6%) | 220/222 (99.1%) | 442/445 (99.3%) | . |
| Yes | 1/510 (0.2%) | 2/505 (0.4%) | 3/1015 (0.3%) | . | 1/223 (0.4%) | 2/222 (0.9%) | 3/445 (0.7%) | . |
| MI within 720 days | | | | 0.9760 | | | | 0.2450 |
| No | 492/510 (96.5%) | 487/505 (96.4%) | 979/1015 (96.5%) | . | 215/223 (96.4%) | 218/222 (98.2%) | 433/445 (97.3%) | . |
| Yes | 18/510 (3.5%) | 18/505 (3.6%) | 36/1015 (3.5%) | . | 8/223 (3.6%) | 4/222 (1.8%) | 12/445 (2.7%) | . |
| Combined incidence of Death, MI, Stent Thrombosis, Stroke or TVR | | | | 0.8752 | | | | 0.8379 |
| No | 460/510 (90.2%) | 454/505 (89.9%) | 914/1015 (90.0%) | . | 209/223 (93.7%) | 207/222 (93.2%) | 416/445 (93.5%) | . |
| Yes | 50/510 (9.8%) | 51/505 (10.1%) | 101/1015 (10.0%) | . | 14/223 (6.3%) | 15/222 (6.8%) | 29/445 (6.5%) | . |
| Revascularization within 720 days | | | | 0.6509 | | | | 0.6042 |
| No | 453/510 (88.8%) | 453/505 (89.7%) | 906/1015 (89.3%) | . | 216/223 (96.9%) | 213/222 (95.9%) | 429/445 (96.4%) | . |
| Yes | 57/510 (11.2%) | 52/505 (10.3%) | 109/1015 (10.7%) | . | 7/223 (3.1%) | 9/222 (4.1%) | 16/445 (3.6%) | . |
| All cause mortality, Def/Prob ST, Stroke, MI or TVR within 720 days | | | | 0.8752 | | | | 0.8379 |
| No | 460/510 (90.2%) | 454/505 (89.9%) | 914/1015 (90.0%) | . | 209/223 (93.7%) | 207/222 (93.2%) | 416/445 (93.5%) | . |
| Yes | 50/510 (9.8%) | 51/505 (10.1%) | 101/1015 (10.0%) | . | 14/223 (6.3%) | 15/222 (6.8%) | 29/445 (6.5%) | . |